Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company builds a biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cyclacel Pharmaceuticals advances Phase II study with promising results and financial boost

Cyclacel Pharmaceuticals made significant progress in Q1 2024 with financing, study advancements, and expense management.
While facing financial challenges and study enrollment timelines, the company remains focused on key milestones and opportunities.
The company's strengths lie in promising study results, solid cash position, and proactive approach to clinical development.
Overall, Cyclacel Pharmaceuticals is poised for growth and value creation in 2024 through strategic advancements.

Cyclacel Pharmaceuticals progresses with fadra, poised for oncology market growth

Cyclacel's fadra program is showing clinical promise and cost efficiency, supported by a stable financial position.
Clear communication of enrollment targets and data disclosure timelines is crucial for maintaining investor confidence.
Optimism for upcoming milestones and engagement opportunities position Cyclacel well for potential growth in the oncology market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. It operates through the United States and United Kingdom geographical segments. The company builds a biopharmaceutical business, which is focused on hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.

Cyclacel Pharmaceuticals Inc 6 % Conv Pfd Shs

BERKELEY HEIGHTS, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2022 financial results on Monday, March 6, 2023. The Company will host a conference call at 4:30pm ET on the same day.

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2022 Financial Results

BERKELEY HEIGHTS, N.J., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that Spiro Rombotis, President and Chief Executive Officer, is scheduled to present an overview of Cyclacel's business and clinical programs at the BIO CEO & Investor Conference taking place at the New York Marriott Marquis Times Square on February 6-9, 2023.

Cyclacel Pharmaceuticals to Participate in the 2023 BIO CEO & Investor Conference

– Determination of Recommended Phase 2 Dose and Start of Phase 2 in 1Q 2023 for Oral Fadraciclib –

Cyclacel Pharmaceuticals Reviews 2022 Achievements and Announces Key Business Objectives for 2023

BERKELEY HEIGHTS, N.J., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that the Company plans to present at the Biotech Showcase and host institutional investor and partnering meetings at this event and a Corporate Access Event organized by LifeSci Partners. Both in-person events are taking place January 9-11, 2023 in San Francisco, California.

Cyclacel Pharmaceuticals to Present at Biotech Showcase and Participate in a Corporate Access Event During the J.P. Morgan Healthcare Conference in January 2023

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC ) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Irina Koffler - LifeSci Advisors Spiro Rombotis - President & Chief Executive Officer Mark Kirschbaum - Senior Vice President & Chief Medical Officer Paul McBarron - Executive Vice President, Finance & Chief Operating Officer Conference Call Participants Ahu Demir - Ladenburg Jonathan Aschoff - ROTH Capital Partners Operator Good afternoon, and welcome to the Cyclacel Pharmaceuticals Third Quarter 2022 Results Conference Call and Webcast. At this time, all participants are in a listen-only mode.

Cyclacel Pharmaceuticals, Inc. (CYCC) Q3 2022 Earnings Call Transcript

- Oral Fadraciclib Daily Dosing Well Tolerated in 18 Evaluable Patients Treated in Dose-Escalation of Phase 1/2 Trial in Advanced Solid Tumors and Lymphoma -

Cyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

BERKELEY HEIGHTS, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce third quarter 2022 financial results on Wednesday, November 9, 2022. The company will host a conference call and live webcast at 4:30 p.m. Eastern Time on the same day.

Cyclacel Pharmaceuticals to Release Third Quarter 2022 Financial Results

Daily dosing of fadraciclib was well tolerated; single agent activity observed across multiple tumor types including 2 PRs in T-cell lymphoma patients Daily dosing of fadraciclib was well tolerated; single agent activity observed across multiple tumor types including 2 PRs in T-cell lymphoma patients

Cyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022

-Program Update on its CDK2/9 Inhibitor, Oral Fadraciclib, and Oral PLK1 Inhibitor, CYC140, for the Treatment of Advanced Solid Tumors and Lymphoma-

Cyclacel Hosting Research & Development Day

- Preliminary Dose Escalation Data to be Presented on Novel CDK2/9 Inhibitor Fadraciclib in Patients with Solid Tumors and Lymphoma - - Preliminary Dose Escalation Data to be Presented on Novel CDK2/9 Inhibitor Fadraciclib in Patients with Solid Tumors and Lymphoma -

Cyclacel Pharmaceuticals To Present Preliminary Data From The Phase 1/2 Clinical Trial Of Oral Fadraciclib At The 34th EORTC-NCI-AACR Symposium

BERKELEY HEIGHTS, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that management will participate in Ladenburg Thalmann's 2022 Healthcare Conference on September 29, 2022 at the Sofitel New York.

Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2022 Healthcare Conference

Cybin

Bright Minds Biosciences

Seelos Therapeutics

Hot biotech penny stocks to watch thanks to MNMD stock today. The post Penny Stocks To Buy Now?

Penny Stocks To Buy Now? 4 Biotech Stocks To Watch This Week

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC ) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Irina Koffler - LifeSci Advisors Spiro Rombotis - President and Chief Executive Officer Paul McBarron - Executive Vice President, Chief Financial Officer and Chief Operating Officer Mark Kirschbaum - Senior Vice President and Chief Medical Officer Conference Call Participants Ahu Demir - Ladenburg Thalmann & Co Jonathan Aschoff - ROTH Capital Partners Operator Good afternoon, and welcome to the Cyclacel Pharmaceuticals Second Quarter 2022 Results Conference Call and Webcast. [Operator Instructions].

Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q2 2022 Results - Earnings Call Transcript

- Oral fadraciclib demonstrated good tolerability with continuous dosing;  anticipate entering Phase 2 POC stage in 2H 2022 –

Cyclacel Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

Cyclacel Pharmaceuticals is an oncology company with two major value drivers in Phase 1/2 trials and overdue catalysts. It trades at an $11 million market cap, with last reported cash of $34.5 million, and mean analyst estimate shows a +1,500% rise potential.

Cyclacel: Trading At Less Than Half Its Cash Value, Near-Term Catalysts, No Obvious Bear Thesis

BERKELEY HEIGHTS, N.J., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter 2022 financial results on Wednesday, August 10, 2022. The company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day.

Cyclacel Pharmaceuticals to Release Second Quarter 2022 Financial Results

Bionano Genomics

Nu Holdings

Penny stocks to buy according to analysts. The post What Are Penny Stocks & 3 To Buy According To Analysts In July appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What Are Penny Stocks & 3 To Buy According To Analysts In July

Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) is adding two dose levels in a protocol amendment to test higher doses of oral fadraciclib before determining the recommended Phase 2 dose anticipated in 2H of 2022, citing the absence of dose-limiting toxicities. Fifteen patients with.

Cyclacel To Test Higher Doses Of Fadraciclib In Solid Tumor Patients

- Completed Enrollment in Phase 1 Dose Escalation with Oral Fadraciclib in Solid Tumors -

Cyclacel Pharmaceuticals Achieves Key Business Objectives in First Half of 2022 and Continues to Advance Clinical Pipeline

BERKELEY HEIGHTS, N.J., June 22, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the election of Kenneth M. Ferguson, Ph.D., to its Board of Directors. Dr. Ferguson was elected by and will represent the 6% Convertible Exchangeable Preferred stockholders.

Cyclacel Pharmaceuticals Announces That Kenneth M. Ferguson, Ph.D.

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC ) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Irina Koffler - LifeSci Advisors Spiro Rombotis - President, CEO & Executive Director Paul McBarron - EVP, CFO, COO, Secretary & Executive Director Mark Kirschbaum - SVP & Chief Medical Officer Conference Call Participants Kevin DeGeeter - Oppenheimer Ahu Demir - Ladenburg Thalmann & Co. Jonathan Aschoff - ROTH Capital Partners Operator Good afternoon, and welcome to the Cyclacel Pharmaceuticals First Quarter 2022 Results Conference Call and Webcast. [Operator Instructions].

Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q1 2022 Results - Earnings Call Transcript

BERKELEY HEIGHTS, N.J., May 04, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce first quarter 2022 financial results on Wednesday, May 11, 2022. The company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day.

Cyclacel Pharmaceuticals to Release First Quarter 2022 Financial Results

- CYC140, a Potent and Selective PLK1 Inhibitor to Be Evaluated as a Single Agent Across Multiple Solid Tumor and Lymphoma Types in Streamlined, Registration-Directed Study - - CYC140, a Potent and Selective PLK1 Inhibitor to Be Evaluated as a Single Agent Across Multiple Solid Tumor and Lymphoma Types in Streamlined, Registration-Directed Study -

Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Cyc140 in Patients With Advanced Solid Tumors and Lymphomas

-New Preclinical Data Highlight Fadraciclib's Apoptosis Enabling Mechanism in Leukemia-

Cyclacel Pharmaceuticals Announces Publication Confirming Fadraciclib Suppresses MCL1 and Synergizes With Venetoclax in Chronic Lymphocytic Leukemia

Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q4 2021 Results - Earnings Call Transcript

News for Cyclacel Pharmaceuticals Stock (CYCC)